07.11.2012 09:30

Early Economic Evaluation from GE Healthcare Highlights the Potential Benefits of Biomarker-Directed Care in Breast Cancer and Renal Cell Carcinoma

GE Healthcare today announced results of three health economic models to estimate the potential cost offsets to the healthcare system of biomarker testing in patients with early breast cancer, metastatic breast cancer and renal cell carcinoma to guide therapy selection. These studies were presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th European Congress in Berlin, Germany.

In two of the studies, the data showed that use of angiogenesis-specific biomarker imaging tests could lead to reduced costs by early determination of response to therapy and early identification of rapid disease progression. Specifically:

  • In a model of 100 UK patients with metastatic breast cancer, one study focused identifying sub-groups in whom such anti-angiogenesis therapies may be of value. The cost consequences of introducing an angiogenesis-specific biomarker imaging test (A-IT) to guide the continuation or removal of anti-angiogenesis (AA) drugs based on a positive or negative determination of early response was evaluated. Per-patient cost savings of £4,561 were realized when A-IT was used to identify treatment response.1 The majority of the savings came from reduced therapy acquisition costs for those patients who ultimately did not receive any benefit from this specific therapy.
  • A second study of a model of 100 UK patients with metastatic renal cell carcinoma evaluated the economic impact of utilizing an angiogenesis-specific imaging (AI) biomarker to identify disease progression versus RECIST monitoring among sunitinib-treated patients. The study revealed that use of the biomarker resulted in per-patient cost savings of £683 per patient.2 In this model, the cost savings reflect the resources freed up which can be used to pay for the AI biomarker.

Additionally, a third study examined the potential impact of better targeting the use of taxane therapies in early breast cancer, by estimating the potential cost impact of a predictive test for taxane response. In a cohort of 100 UK patients, applying an in-vitro biomarker that could predict patient response led to an average cost savings (as measured by treatment costs and costs associated with adverse events resulting from treatment) of £1,398 per patient.3

"We recognize that early economic evaluations of potential biomarker-guided treatment pathways can provide useful preliminary information to developers, clinicians and payers,” said Ger Brophy, Head of New Product Development, GE Healthcare Medical Diagnostics. "Prolonged therapy exposes non-responding patients to potential risks without clinical benefit, resulting in misallocated healthcare resources which could be directed elsewhere. Our new diagnostics need to play a part not only in raising the quality of healthcare, but also in making efficient provision of good care more possible. While further clinical development of these tests is needed; collectively, these models show that utilizing such tests may have the potential to reduce both the costs of treatment and also the costs of managing treatment-related adverse events.”

About GE Healthcare

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.

Our "healthymagination" vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality and efficiency around the world. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our web site at www.gehealthcare.com.

For our latest news, please visit http://newsroom.gehealthcare.com.


1 Paramore CL, Bodnar C, Knopf KB. Estimating economic impact of angiogenesis-specific imaging in metastatic breast cancer. Data presented at ISPOR 15th European Congress, 3-7 November 2012, Berlin, Germany.

2 Gruschkus SK, Bodnar C, Dhamane A, et al. Economic evaluation of reduced futile 1st line therapy in metastatic renal cell carcinoma patients using early angiogenesis-specific imaging. Data presented at ISPOR 15th European Congress, 3-7 November 2012, Berlin, Germany.

3 Brown RE, Bodnar C, Knopf KB. Economic analysis of a predictive test for taxane response in early breast cancer patients in the UK. Data presented at ISPOR 15th European Congress, 3-7 November 2012, Berlin, Germany.


Nachrichten zu General Electric (GE) Co.

  • Relevant6
  • Alle6
  • vom Unternehmen
  • Peer Group
  • ?
Im Vorfeld anstehender Quartalszahlen erhielt die Aktie von General Electric ziemlich viele Vorschusslorbeeren, möglicherweise etwas zu viele. Mit dem nachfolgenden Knock-Out-Put setzen Anleger auf einen Rücksetzer.
03:19 Uhr
A Rising GE Floats All Industrials (EN, The Wall Street Journal Deutschland)

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu General Electric (GE) Co.

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
05.10.2015General Electric (GE) kaufenBarclays Capital
16.09.2015General Electric (GE) kaufenCredit Suisse Group
10.09.2015General Electric (GE) kaufenIndependent Research GmbH
08.09.2015General Electric (GE) HoldSociété Générale Group S.A. (SG)
12.08.2015General Electric (GE) buyMorningstar
05.10.2015General Electric (GE) kaufenBarclays Capital
16.09.2015General Electric (GE) kaufenCredit Suisse Group
10.09.2015General Electric (GE) kaufenIndependent Research GmbH
12.08.2015General Electric (GE) buyMorningstar
20.04.2015General Electric (GE) OverweightBarclays Capital
08.09.2015General Electric (GE) HoldSociété Générale Group S.A. (SG)
06.01.2015General Electric (GE) HoldDeutsche Bank AG
22.07.2013General Electric (GE) haltenBernstein
21.03.2013General Electric (GE) haltenMorgan Stanley
29.01.2013General Electric (GE) haltenHamburger Sparkasse AG (Haspa)
04.12.2009General Electric reduzierenIndependent Research GmbH
19.10.2009General Electric reduzierenIndependent Research GmbH
20.07.2009General Electric reduzierenIndependent Research GmbH
20.04.2009General Electric reduzierenIndependent Research GmbH
26.01.2009General Electric reduzierenIndependent Research GmbH
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für General Electric (GE) Co. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen
Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"

mehr General Electric (GE) Co. Analysen

Heute im Fokus

DAX geht mit über 10.000 Punkten ins Wochenende -- Dow Jones im Plus -- VW-Stammaktien mit rätselhaftem Kurssprung -- Fed-Banker erwartet Zinswende noch 2015 -- Schaeffler-IPO, E.ON, RWE im Fokus

Alcoa-Fehlstart in neue Berichtsaison. US-Repräsentantenhaus stimmt für Abschaffung von Rohöl-Exportverbot. US-Regulierer setzen VW Ultimatum in Abgas-Affäre. Italien bringt staatliche Post an die Börse - Milliardenerlös erwartet. Experten sehen Chancen für "Goldenen Oktober" am Aktienmarkt.
Wen sieht die BrandZ-Studie vorn?
Die öffentliche Verschwendung
Diese Aktien sind auf den Kauflisten der Experten

Die 5 beliebtesten Top-Rankings

Was verdient man bei Google?
Welcher Darsteller verdient am meisten?
Wer waren die Aktienstars des deutschen Leitindex?
Produkte von Google, die keiner kennt
Heute sind sie Milliardäre
mehr Top Rankings


Warum kaufen Sie Zertifikate?